Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · MA, CA, WA, NC, NJ, DE · Aug 10, 2012 → May 4, 2026
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:15 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Andrew Levin is listed as an executive officer and director on 38 SEC Form D filings by 21 issuers between Aug 2012 and May 2026. Largest by amount reported sold: Metagenomi Technologies, LLC (Emeryville, CA — biotechnology — 2021; $175.4M reported sold to 29 investors), Aktis Oncology, Inc. (Boston, MA — biotechnology — 2024; $175M reported sold to 39 investors), Solstice Oncology, Inc. (Boston, MA — biotechnology — 2026; $121.3M reported sold to 8 investors), Triana Biomedicines, Inc. (Lexington, MA — pharmaceuticals — 2020; $120.1M reported sold to 20 investors), Climb Bio, Inc. (Wellesley Hills, MA — biotechnology — 2019–2026; $120M reported sold to 22 investors) and 16 more (all listed below).
What this means That is a lot of deals — 21 separate companies raised money with this person listed as executive officer and director, over about 14 years. Across those companies the filings report $1.3B sold in total.
Listed alongside Simon Tate (7 shared filings), Liam Ratcliffe (6 shared filings), Adam J. Rosenberg (5 shared filings), David-Alexandre Gros (5 shared filings), STEPHEN THOMAS (5 shared filings) and 101 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Andrew. Each name links to their own page.
The issuers belong to 3 sponsor groups: Athenen (2 issuers, $17M reported sold, 2019–2020), Avalon (15 issuers, $705.3M reported sold, 2010–2025) and Arvinas (2 issuers, $36M reported sold, 2013–2019).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 2 bankruptcy cases matching the name listed in Key records below.
What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 38 public filings for Andrew Levin and found 14 differences, 1 worth asking the sponsor about: 12 Form Ds were filed more than 15 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Andrew Levin has not run yet — it is joining a line of 35,388 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.
Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:15 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Andrew Levin..
State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).
2 cases: 2 closed (disposition not in docket feed)
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:15 AM ET.
Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
14 differences found between the filings for Andrew Levin — 1 worth asking about (compared 38 filings on Oct 24, 2026)
United States Bankruptcy Court, D. New Jersey docket "PNC Bank v. Litchman" filed Oct 23, 2000, closed Feb 27, 2002. Manuel Litchman (listed on the same filings) is listed as Defendant ("Litchman"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
United States Bankruptcy Court, N.D. California docket "First USA Bank, N.A. v. Bernales" filed Feb 18, 2000, closed Mar 23, 2000. Sebastian Bernales (listed on the same filings) is listed as Defendant ("Bernales"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
Synthorx, Inc. (last filing Apr 27, 2018; $26,545,402 sold of $63,708,953); IMMUNETICS, INC. (last filing Mar 10, 2014; $835,000 sold of $3,000,000). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Form D filed 141 days after the first sale — Pahr Therapeutics, Inc. · Form D filed 178 days after the first sale — Superluminal Medicines, Inc. · Form D filed 321 days after the first sale — Clear Creek Bio, Inc. · Form D filed 22 days after the first sale — Slate Medicines, Inc. · Form D filed 17 days after the first sale — Solstice Oncology, Inc. · and 7 more
What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.
No amendment in the last 12 months on an offering that may still be open — Pahr Therapeutics, Inc. (latest filing Jul 18, 2025) · No amendment in the last 12 months on an offering that may still be open — Navigator Medicines, Inc. (latest filing Sep 5, 2024) · No amendment in the last 12 months on an offering that may still be open — Superluminal Medicines, Inc. (latest filing Sep 4, 2024) · No amendment in the last 12 months on an offering that may still be open — Climb Bio, Inc. (latest filing Nov 3, 2020) · No amendment in the last 12 months on an offering that may still be open — Athenen Therapeutics, Inc. (latest filing Jul 31, 2020) · and 10 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
Andrew Levin's role changed at Climb Bio, Inc.: executive officer, director → director · Andrew Levin's role changed at Climb Bio, Inc.: director → executive officer, director · Andrew Levin's role changed at Climb Bio, Inc.: executive officer, director → director · Andrew Levin's role changed at Athenen Therapeutics, Inc.: executive officer, director → director
What this means Roles on Form D are self-reported. Ask who runs the company today.
The Apr 1, 2025 filing says $124,195,815 offered; the Dec 16, 2025 Form D/A says $144,195,814.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
The Oct 4, 2019 filing says $10,000,002 offered; the Jul 31, 2020 Form D/A says $15,000,003.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
The Feb 19, 2019 filing says $12,240,000 offered; the Oct 23, 2019 Form D/A says $16,302,501.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
"Pharmaceuticals" (Jul 9, 2018 to Jul 2, 2020); then "Biotechnology" (Apr 1, 2025 to Dec 16, 2025).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Pharmaceuticals" (Feb 19, 2019 to May 28, 2021); then "Biotechnology" (Jul 2, 2024 to May 4, 2026).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
This page covers filings where the address state is MA or CA or WA or NC or NJ or DE. A separate record, "Andrew I. Levin" with address state MN, is listed on 1 filing — most recently by Clayton 42 OZ Fund LLC (Jul 7, 2023). Both records have filings in the same period (Jul 7, 2023).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
Address moved from Wilmington, DE to Wellesley Hills, MA — Climb Bio, Inc. · Address moved from Waltham, MA to Boston, MA — Superluminal Medicines, Inc. · Address moved from Boston, MA to Waltham, MA — Superluminal Medicines, Inc. · Address moved from Redmond, WA to Wilmington, DE — Climb Bio, Inc. · Address moved from Boston, MA to Redmond, WA — Climb Bio, Inc. · and 2 more
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
MA on 27 filings (Aug 10, 2012 to May 4, 2026); CA on 5 filings (Jul 28, 2016 to Mar 29, 2021); WA on 2 filings (Nov 3, 2020 to May 28, 2021); NC on 1 filing (Dec 6, 2022); DE on 2 filings (Jul 2, 2024 to Jul 2, 2024); NJ on 1 filing (Sep 5, 2024).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
1 of 35 offerings reports sales commissions totalling $6,304,577; 0 report finder's fees; 0 report proceeds to related persons.
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| May 4, 2026 D Climb Bio, Inc. File 021-582793 | $6,304,577 | $0 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ Piper Sandler and Co. BrokerCheck CRD 665 ↗ Raymond James & Associates, Inc. BrokerCheck CRD 705 ↗ BTIG, LLC BrokerCheck CRD 122225 ↗ Robert W. Baird & Co. Incorporated BrokerCheck CRD 8158 ↗ H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗ | EDGAR ↗ |
| Mar 11, 2026 D Slate Medicines, Inc. File 021-576090 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 9, 2026 D Solstice Oncology, Inc. File 021-575833 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 23, 2026 D Lonestar Medicines, Inc. File 021-574347 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 16, 2025 D/A Imbria Pharmaceuticals, Inc. File 021-542691 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 26, 2025 D Superluminal Medicines, Inc. File 021-555850 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 18, 2025 D Pahr Therapeutics, Inc. File 021-552238 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 2, 2024 D Aktis Oncology, Inc. File 021-525672 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 5, 2024 D Navigator Medicines, Inc. File 021-523299 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Sep 4, 2024 D Superluminal Medicines, Inc. File 021-523131 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 2, 2024 D Climb Bio, Inc. File 021-517682 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 2, 2024 D Climb Bio, Inc. File 021-517684 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 28, 2023 D Superluminal Medicines, Inc. File 021-490789 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 6, 2022 D Lusaris Therapeutics, Inc. File 021-466642 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 28, 2021 D Climb Bio, Inc. File 021-401012 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Mar 29, 2021 D Metagenomi Technologies, LLC File 021-393845 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 10, 2020 D Cytek BioSciences, Inc. File 021-380200 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 3, 2020 D Climb Bio, Inc. File 021-379616 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 31, 2020 D/A Athenen Therapeutics, Inc. File 021-350383 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 6, 2020 D Triana Biomedicines, Inc. File 021-370304 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 2, 2020 D Imbria Pharmaceuticals, Inc. File 021-370161 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 8, 2020 D Aerovate Therapeutics, Inc. File 021-357485 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 23, 2019 D/A Climb Bio, Inc. File 021-333123 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 23, 2019 D Climb Bio, Inc. File 021-351683 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 11, 2019 D Clear Creek Bio, Inc. File 021-350837 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 9, 2019 D Arcuate Therapeutics, Inc. File 021-350699 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 9, 2018 D Imbria Pharmaceuticals, Inc. File 021-316241 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 7, 2018 D Clear Creek Bio, Inc. File 021-311817 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 27, 2018 D Synthorx, Inc. File 021-311122 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Apr 5, 2018 D ARVINAS, INC. File 021-309449 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or managers. | None listed on this filing | EDGAR ↗ |
| Jun 28, 2017 D CleanBreak, Inc. File 021-289609 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 28, 2016 D Synthorx, Inc. File 021-267863 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Oct 23, 2015 D ARVINAS, INC. File 021-249974 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or directors. | None listed on this filing | EDGAR ↗ |
| Mar 10, 2014 D IMMUNETICS, INC. File 021-213271 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Aug 10, 2012 D IMMUNETICS, INC. File 021-182510 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Andrew Levin on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $120M from 22 investors (100% of the $110.1M target) as of the latest filing. Andrew is listed as director, executive officer on 8 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $10M from 6 investors (8% of the $130M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $121.3M from 8 investors (41% of the $298.4M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $25M from 4 investors (56% of the $45M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $66.7M from 10 investors (46% of the $144.2M target) as of the latest filing. Andrew is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $65.5M from 16 investors (100% of the $5M target) as of the latest filing. Andrew is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $4.67M from 4 investors (33% of the $14M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $175M from 39 investors (100% of the $175M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $50M from 4 investors (50% of the $100M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $60.2M from 9 investors (100% of the $60.2M target) as of the latest filing. Andrew is listed as executive officer, director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $175.4M from 29 investors (100% of the $10M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $120M from 14 investors (100% of the $120M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $12M from 3 investors (80% of the $15M target) as of the latest filing. Andrew is listed as director, executive officer on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $120.1M from 20 investors (100% of the $14M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $75.8M from 9 investors (100% of the $2.5M target) as of the latest filing. Andrew is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $6.12M from 7 investors (100% of the $1.63M target) as of the latest filing. Andrew is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $5M from 3 investors (50% of the $10M target) as of the latest filing. Andrew is listed as executive officer, director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $26.5M from 10 investors (42% of the $63.7M target) as of the latest filing. Andrew is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $55M from 22 investors (100% of the $55M target) as of the latest filing. Andrew is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $2M from 2 investors (50% of the $4M target) as of the latest filing. Andrew is listed as executive officer, director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $835K from 24 investors (28% of the $3M target) as of the latest filing. Andrew is listed as executive officer, director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Liam Ratcliffe is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Adam J. Rosenberg is on 6 issuers in total — a repeat sponsor. Their page lists every one.
STEPHEN THOMAS is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Joshua Resnick is on 13 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Dylan Morris is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Sean Cassidy is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Jay Lichter is on 10 issuers in total — a repeat sponsor. Their page lists every one.
Ron Zwanziger is on 7 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Tim Shannon is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Kush Parmar is on 17 issuers in total — a repeat sponsor. Their page lists every one.
Stephen Squinto is on 16 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
Listed on the same filings as Andrew Levin. Their page shows their other deals.
One team, 2 deal companies. Andrew Levin is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Andrew Levin.
One team, 15 deal companies. Andrew Levin is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Andrew Levin.
One team, 2 deal companies. Andrew Levin is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Andrew Levin.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).
None of the 21 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Andrew Levin by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 21 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Andrew Levin is listed on: none on file. No website or social profile named in Aktis Oncology, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #88,652 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (Boston, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Andrew Levin appears on a new Form D, or when a court case or SEC action is matched to them. See plans →